Julie A. Margenthaler
Expertise in
14
conditions

Dr. Julie A. Margenthaler

Surgical Oncology | General Surgery
Washington University
4921 Parkview Pl, 
Saint Louis, MO 
Accepting New Patients
Expertise in
14
conditions
Washington University
4921 Parkview Pl, 
Saint Louis, MO 

Overview

Julie Margenthaler is a Surgical Oncologist and a General Surgeon in Saint Louis, Missouri. Dr. Margenthaler is highly rated in 14 conditions, according to our data. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Intraductal Papilloma, Mastectomy, and Lymphadenectomy. Dr. Margenthaler is currently accepting new patients.

Her clinical research consists of co-authoring 160 peer reviewed articles and participating in 18 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Surgical Oncology
General Surgery

Licenses

Surgery in MO

Hospital Affiliations

Alton Memorial Hospital
Barnes-Jewish West County Hospital
Barnes Jewish Hospital
Memorial Hospital
Missouri Baptist Medical Center

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Cox Health
  • EPO
  • PPO
Dean Health
  • EPO
  • HMO
  • POS
  • PPO
Essence Healthcare
  • INSURANCE PLAN
  • MEDICARE MAPD
Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

WASHINGTON UNIVERSITY
4921 Parkview Pl, Saint Louis, MO 63110
Other Locations
WASHINGTON UNIVERSITY
660 S Euclid Ave, Campus Box 8109, St Louis, MO 63110
WASHINGTON UNIVERSITY
1 Barnes Jewish Hospital Plz, Suite 200, Saint Louis, MO 63110
WASHINGTON UNIVERSITY
12634 Olive Blvd, Saint Louis, MO 63141

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

18 Clinical Trials

A Phase II Trial of Neoadjuvant PD 0332991, a Cyclin-Dependent Kinase (Cdk) 4/6 Inhibitor, in Combination With Anastrozole in Women With Clinical Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer
A Phase II Trial of Neoadjuvant PD 0332991, a Cyclin-Dependent Kinase (Cdk) 4/6 Inhibitor, in Combination With Anastrozole in Women With Clinical Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 09, 2025
Intervention Type: Procedure, Drug
Study Drugs: PD0332991, Anastrozole, Goserelin
Study Phase: Phase 2
Randomized Clinical Trial of RANKL Inhibition With Denosumab on Mammographic Density in Premenopausal Women With Dense Breasts (TRIDENT)
Randomized Clinical Trial of RANKL Inhibition With Denosumab on Mammographic Density in Premenopausal Women With Dense Breasts (TRIDENT)
Enrollment Status: Active_not_recruiting
Publish Date: October 16, 2025
Intervention Type: Procedure, Drug
Study Drugs: Denosumab, Calcium, Vitamin D3
Study Phase: Phase 2
Evaluation of LS301 Uptake in Tumors of Patients Undergoing Partial Mastectomy and Sentinel Lymph Node Biopsy for Breast Cancer
Evaluation of LS301 Uptake in Tumors of Patients Undergoing Partial Mastectomy and Sentinel Lymph Node Biopsy for Breast Cancer
Enrollment Status: Terminated
Publish Date: August 17, 2025
Intervention Type: Drug, Procedure, Device
Study Drug: LS301
Study Phase: Phase 1/Phase 2
Evaluation of Single Fraction Accelerated Partial Breast Irradiation vs. Five Fraction Accelerated Partial Breast Irradiation for Low-risk Stage 0 and I Breast Carcinoma - BreaStBRT
Evaluation of Single Fraction Accelerated Partial Breast Irradiation vs. Five Fraction Accelerated Partial Breast Irradiation for Low-risk Stage 0 and I Breast Carcinoma - BreaStBRT
Enrollment Status: Active_not_recruiting
Publish Date: May 07, 2025
Intervention Type: Radiation
Study Phase: Not Applicable
A Phase 1B Clinical Trial to Evaluate the Safety and Immune Response to a Mammaglobin-A DNA Vaccine in ER+, HER2- Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy or Chemotherapy
A Phase 1B Clinical Trial to Evaluate the Safety and Immune Response to a Mammaglobin-A DNA Vaccine in ER+, HER2- Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy or Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: April 17, 2025
Intervention Type: Biological, Procedure
Study Drug: Mammaglobin-A DNA Vaccine
Study Phase: Phase 1
Evaluation of Three Fraction Accelerated Partial Breast Irradiation as the Sole Method of Radiation Therapy for Low-risk Stage 0 and I Breast Carcinoma
Evaluation of Three Fraction Accelerated Partial Breast Irradiation as the Sole Method of Radiation Therapy for Low-risk Stage 0 and I Breast Carcinoma
Enrollment Status: Active_not_recruiting
Publish Date: March 24, 2025
Intervention Type: Radiation, Procedure
Study Phase: Not Applicable
PECS Block vs. Multimodal Analgesia for Prevention of Persistent Postoperative Pain in Breast Surgery
PECS Block vs. Multimodal Analgesia for Prevention of Persistent Postoperative Pain in Breast Surgery
Enrollment Status: Completed
Publish Date: December 24, 2024
Intervention Type: Drug
Study Phase: Phase 2
RANKL Inhibition and Breast Tissue Biomarkers in Premenopausal Women With Dense Breasts
RANKL Inhibition and Breast Tissue Biomarkers in Premenopausal Women With Dense Breasts
Enrollment Status: Completed
Publish Date: October 16, 2024
Intervention Type: Drug, Procedure
Study Phase: Early Phase 1
Evaluation of Single Fraction High-Gradient Partial Breast Irradiation as the Sole Method of Radiation Therapy for Low-Risk Stage 0 and I Breast Carcinoma
Evaluation of Single Fraction High-Gradient Partial Breast Irradiation as the Sole Method of Radiation Therapy for Low-Risk Stage 0 and I Breast Carcinoma
Enrollment Status: Completed
Publish Date: July 11, 2024
Intervention Type: Radiation
Study Phase: Not Applicable
The Impact of Operative Approach on Long Term Function Outcomes and Pain in Implant-based Post-mastectomy Breast Reconstruction
The Impact of Operative Approach on Long Term Function Outcomes and Pain in Implant-based Post-mastectomy Breast Reconstruction
Enrollment Status: Terminated
Publish Date: June 05, 2024
Intervention Type: Other
A Randomized Phase 1 Trial of Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy
A Randomized Phase 1 Trial of Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy
Enrollment Status: Terminated
Publish Date: May 28, 2024
Intervention Type: Device, Biological, Drug, Procedure
Study Drugs: Durvalumab, Neoantigen DNA vaccine
Study Phase: Phase 1
A Single-Blinded Randomized Prospective Trial to Compare Outcomes Between Two Acellular Dermal Matrices Used for Immediate, Post-Mastectomy Breast Reconstruction
A Single-Blinded Randomized Prospective Trial to Compare Outcomes Between Two Acellular Dermal Matrices Used for Immediate, Post-Mastectomy Breast Reconstruction
Enrollment Status: Completed
Publish Date: May 06, 2023
Intervention Type: Procedure, Other
Study Phase: Phase 2
A Co-clinical Trial in Triple Negative Breast Cancer Patients With Genoproteomic Discovery
A Co-clinical Trial in Triple Negative Breast Cancer Patients With Genoproteomic Discovery
Enrollment Status: Terminated
Publish Date: November 07, 2022
Intervention Type: Drug, Procedure
Study Drugs: Docetaxel, Carboplatin
Study Phase: Phase 2
A Phase II Randomized Trial Evaluating the Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Bone Marrow Disseminated Tumor Cells
A Phase II Randomized Trial Evaluating the Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Bone Marrow Disseminated Tumor Cells
Enrollment Status: Terminated
Publish Date: November 01, 2022
Intervention Type: Drug, Biological
Study Drugs: Doxorubicin, Trastuzumab, Cyclophosphamide, Paclitaxel, Epirubicin, Docetaxel, Carboplatin, Fluorouracil
Study Phase: Phase 2
A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine Strategy in Patients With Persistent Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy
A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine Strategy in Patients With Persistent Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy
Enrollment Status: Withdrawn
Publish Date: March 10, 2022
Intervention Type: Biological, Drug
Study Phase: Phase 1
A Phase II Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab as Neoadjuvant Treatment of Stage II-III ER+ HER2+ Breast Cancer (PALTAN)
A Phase II Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab as Neoadjuvant Treatment of Stage II-III ER+ HER2+ Breast Cancer (PALTAN)
Enrollment Status: Terminated
Publish Date: September 29, 2021
Intervention Type: Procedure, Drug, Genetic, Biological
Study Phase: Phase 2
Shave Margins in Breast Conservation Therapy (SMART): A Randomized Controlled Trial
Shave Margins in Breast Conservation Therapy (SMART): A Randomized Controlled Trial
Enrollment Status: Terminated
Publish Date: June 25, 2020
Intervention Type: Device, Behavioral, Procedure, Other
Study Phase: Phase 2
A Prospective Randomized Trial of Sentinel Lymph Node Biopsy Versus no Additional Staging in Patients With Clinical T1-T2 N0 M0 Invasive Breast Cancer and Negative Axillary Ultrasound
A Prospective Randomized Trial of Sentinel Lymph Node Biopsy Versus no Additional Staging in Patients With Clinical T1-T2 N0 M0 Invasive Breast Cancer and Negative Axillary Ultrasound
Enrollment Status: Terminated
Publish Date: March 05, 2019
Intervention Type: Procedure
Study Phase: Not Applicable
View 17 Less Clinical Trials

160 Total Publications

ASO Visual Abstract: Impact of Sociodemographic and Clinical Factors on Postoperative Outcomes Following Immediate Post-mastectomy Autologous Breast Reconstruction.
ASO Visual Abstract: Impact of Sociodemographic and Clinical Factors on Postoperative Outcomes Following Immediate Post-mastectomy Autologous Breast Reconstruction.
Journal: Annals of surgical oncology
Published: October 08, 2025
Similar Doctors
Expertise in
14
conditions
Dr. Rebecca L. Aft
Surgical Oncology | General Surgery
Expertise in
14
conditions
Dr. Rebecca L. Aft
Surgical Oncology | General Surgery

Washington University

4921 Parkview Pl, 
Saint Louis, MO 
 (0.1 miles away)
314-362-4699
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Rebecca Aft is a Surgical Oncologist and a General Surgeon in Saint Louis, Missouri. Dr. Aft is highly rated in 14 conditions, according to our data. Her top areas of expertise are Breast Cancer, Inflammatory Breast Cancer, Paget Disease of the Breast, Mastectomy, and Lymphadenectomy. Dr. Aft is currently accepting new patients.

Expertise in
21
conditions
Dr. William E. Gillanders
Surgical Oncology | General Surgery
Expertise in
21
conditions
Dr. William E. Gillanders
Surgical Oncology | General Surgery

Washington University

4921 Parkview Pl, 
Saint Louis, MO 
 (0.1 miles away)
314-362-4699
Languages Spoken:
English
See accepted insurances
Accepting New Patients

William Gillanders is a Surgical Oncologist and a General Surgeon in Saint Louis, Missouri. Dr. Gillanders is highly rated in 21 conditions, according to our data. His top areas of expertise are Breast Cancer, Hyperparathyroidism, Thyroid Cancer, Parathyroidectomy, and Mastectomy. Dr. Gillanders is currently accepting new patients.

Expertise in
42
conditions
Dr. Ryan Fields
General Surgery
Expertise in
42
conditions
Dr. Ryan Fields
General Surgery

Washington University

660 S Euclid Ave, 
Saint Louis, MO 
 (0.2 miles away)
314-286-1694
Languages Spoken:
English
See accepted insurances

Ryan Fields is a General Surgeon in Saint Louis, Missouri. Dr. Fields is highly rated in 42 conditions, according to our data. His top areas of expertise are Neuroendocrine Tumor, Pancreatic Cancer, Gallbladder Cancer, Pancreaticoduodenectomy, and Pancreatectomy.

Frequently Asked Questions about Dr. Julie A. Margenthaler

How do I make an appointment with Dr. Julie A. Margenthaler?

You can book an appointment with Dr. Julie A. Margenthaler by calling their office at 314-362-4699. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Julie A. Margenthaler a top-rated expert for Mastectomy?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Julie A. Margenthaler is classified as an Elite expert for Mastectomy, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Julie A. Margenthaler specialize in?

While Dr. Julie A. Margenthaler is a Surgical Oncology, they have specific expertise in Mastectomy, Breast Cancer, and Paget Disease of the Breast. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Surgical Oncology.

Does Dr. Julie A. Margenthaler participate in research or clinical trials?

Yes. Dr. Julie A. Margenthaler has published 160 articles and abstracts on conditions like Mastectomy. You can view a list of Dr. Julie A. Margenthaler's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Julie A. Margenthaler accept my insurance?

Dr. Julie A. Margenthaler accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 314-362-4699 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Margenthaler's expertise for a condition
ConditionClose
View All 8 Advanced Conditions
View All 16 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile